Pfizer has reached an agreement with the Trump administration, ensuring the company’s branded and patented drugs will avoid 100% import tariffs for at least three years while dramatically expanding manufacturing and research investments across the United States. The company has committed an additional $70 billion for U.S.-based research, development, and capital projects—a move that builds on more than $83 billion in domestic biotech investment over the previous seven years and promises to bolster the country’s leadership in biopharmaceutical innovation.
The expanded investment will be channeled through Pfizer’s 13 U.S. manufacturing and distribution sites and 7 major R&D facilities, supporting a workforce of over 31,000 employees engaged in developing therapies, including those in oncology, obesity, vaccines, and immunology. This focus aligns with the Trump administration’s goals to boost domestic pharmaceutical output and innovation, providing “certainty from tariffs and clarity on pricing” that had previously clouded the industry’s outlook.
As part of the deal, Pfizer also agreed to offer deep discounts for key drugs—up to 85% on some products—via the government’s new TrumpRx.gov purchasing platform. American Medicaid patients, in particular, will gain access to medicines at the lowest global price points, as the agreement sets a benchmark for “most favored nation” pricing and ramps up industry-wide pressure on other manufacturers to negotiate similar terms or risk facing punitive tariffs.
Pfizer’s CEO Albert Bourla stated the agreement provides the “certainty and stability” the company needs to move aggressively on next-generation cures while simultaneously supporting U.S. economic strength and global competitiveness in drug development. The deal is regarded by the administration as a model for future pharma policy and is expected to accelerate the return of high-value drug manufacturing to American soil.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!